Clinician FAQ
Frequently asked questions for healthcare professionals
Common clinical questions about hirudotherapy, answered with references to published guidelines and the ASH knowledge base. This FAQ is intended for healthcare professionals considering or currently performing leech therapy.
Regulatory & Legal
What is the FDA status of medicinal leeches?
Medicinal leeches are FDA 510(k)-cleared medical devices (product code NRN). Cleared for two indications: (1) adjunct to healing of graft tissue with venous congestion, and (2) restoring circulation in blocked veins. In December 2024, regulatory responsibility transferred from CDRH to CBER. Three companies hold active 510(k) clearances: Ricarimpex SAS, Biopharm Ltd, and Carolina Biological Supply Co.
Is off-label use of medicinal leeches legal?
Yes. The FDA regulates manufacturers, not the practice of medicine. Licensed practitioners retain authority to use cleared devices for indications supported by their clinical judgment. However, off-label use requires: (a) informed consent with explicit off-label disclosure, (b) awareness that no regulatory body has evaluated safety/effectiveness for the off-label indication, and (c) understanding of insurance implications (most off-label uses are not covered).
Who can legally perform hirudotherapy?
No state explicitly addresses hirudotherapy. MD/DO: authorized in all 50 states. NP: independent in 26 states + DC. PA: under physician supervision. RN: under physician orders with institutional credentialing. ND: uncertain, state-dependent (~24 states licensed). C.H.P.: private credential, not a license — high legal risk without underlying healthcare licensure.
Infection Prevention
What is the Aeromonas infection risk?
Without prophylaxis: 7-20%. With appropriate prophylaxis: <5%, approaching 0% in well-controlled series (Nguyen et al., 2012). Aeromonas hydrophila and related species are obligate endosymbionts of the leech gut — the infection risk is inherent to the therapy. Infection can manifest up to 26 days post-treatment and reduces tissue salvage from 88.3% to 37.4% (Whitaker et al., 2012).
What antibiotic prophylaxis should I use?
First-line: Ciprofloxacin 500 mg BID or TMP-SMX DS BID. Recommended: Combination (both) per Herlin et al. (2017), given emerging ciprofloxacin resistance (43% in environmental isolates). Begin before first application; continue throughout course + 24-48h after last application. Never use first-generation cephalosporins (intrinsic resistance). For high-volume centers: batch-level surveillance cultures recommended.
Is prophylaxis failure possible?
Yes. Five published cases of ciprofloxacin-resistant Aeromonas infection following leech therapy (2013-2025). Plasmid-mediated quinolone resistance (PMQR) genes found in 42% of environmental Aeromonas isolates. Combination prophylaxis and batch surveillance reduce this risk.
Clinical Practice
How much blood does each leech remove?
5-15 mL during feeding + 10-50 mL post-detachment oozing = 15-65 mL total per leech. For a session with 6 leeches, anticipate 90-390 mL. In serial surgical therapy (3-6 leeches every 4 hours for 5 days), cumulative loss may reach 2-5 liters. 49.75% of microsurgical leech patients require transfusion (Whitaker et al., 2012).
What if the leech won’t attach?
Ensure skin is warm, clean, and free of chemicals (no alcohol, betadine, perfume). Prick skin with sterile needle to produce a blood droplet (most reliable attractant). Try a different leech. Use the syringe guide method for precision. Persistent refusal by multiple leeches to attach to a specific tissue area may indicate nonviable tissue — an ominous prognostic sign in surgical contexts.
What are the absolute contraindications?
Arterial insufficiency at the application site, hemophilia or hemorrhagic diathesis, hematological malignancies, severe anemia (Hgb <8 g/dL without transfusion plan), active sepsis, HIV infection, and decompensated hepatobiliary disease. Relative contraindications include pregnancy, immunosuppression, keloid tendency, and therapeutic anticoagulation without surgical coordination.
Insurance & Reimbursement
What CPT code should I use?
CPT 17999 (unlisted procedure, skin/mucous membrane/subcutaneous tissue) is the primary code. Requires procedure notes and cover letter. HCPCS C1765 for leech supply in hospital outpatient. There is no dedicated CPT code for leech therapy — reimbursement is case-by-case.
Will insurance cover leech therapy?
For the FDA-cleared indication (venous congestion in flaps/replants): likely yes. Aetna CPB 0556 explicitly covers flap/replant salvage. For off-label indications (OA, thrombophlebitis, etc.): unlikely. Most payers consider non-surgical use experimental. The self-pay market (~$200/session, $1,400-$1,800 per course) is the primary revenue model for outpatient practices.
Training & Startup
What training do I need?
There is no government-recognized certification. The C.H.P. credential from the Academy of Hirudotherapy (200+ hours didactic, 100-200 hours clinical, ~$10,000) is the most structured program. Hospital-based surgeons and nurses typically train through institutional protocols. Eight core competency domains should be demonstrated before treating patients (see Practitioner Training page).
What does it cost to start a hirudotherapy practice?
$2,000-$5,000 for equipment and supplies (excluding leeches and facility costs). Initial leech stock (50-100): $350-$1,500. Monthly ongoing: biohazard waste pickup ($50-$150/month), leech reorders, disposables. Revenue from self-pay sessions (~$200 each) provides the primary income for outpatient practices.